ArticleClinical rheumatology2012
Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement.
Article in Clinical rheumatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Serum TRAIL predicts severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study.Internal and emergency medicine · 2022Article
- Serum markers of cardiac complications in a systemic sclerosis cohort.Scientific reports · 2022Article
- Abnormal Changes of Monocyte Subsets in Patients With Sjögren's Syndrome.Frontiers in immunology · 2022Article
- Molecular Mode of Action of TRAIL Receptor Agonists-Common Principles and Their Translational Exploitation.Cancers · 2019Review
- Serum-soluble TRAIL: a potential biomarker for disease activity in myositis patients.Clinical rheumatology · 2019Article
- Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma.Nature communications · 2019Article
- Divergent Roles for TRAIL in Lung Diseases.Frontiers in medicine · 2018Review
- A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis.Genome medicine · 2017Article
- Cytokines in the immunopathology of systemic sclerosis.Seminars in immunopathology · 2015Review
- Soluble TRAIL Concentration in Serum Is Elevated in People with Hypercholesterolemia.PloS one · 2015Article
- Increased serum TRAIL and DR5 levels correlated with lung function and inflammation in stable COPD patients.International journal of chronic obstructive pulmonary disease · 2015Article
- Soluble TRAIL in normal pregnancy and acute pyelonephritis: a potential explanation for the susceptibility of pregnant women to microbial products and infection.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2013Article
- Transcriptional regulation of tumour necrosis factor-related apoptosis-inducing ligand.Cellular and molecular life sciences : CMLS · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been reported to be involved in the pathophysiology of some autoimmune diseases as systemic lupus erythematosus, ankylosing spondylitis, and multiple sclerosis. The aim of this study was to assess serum TRAIL concentration in systemic sclerosis (SSc) patients and to investigate its possible association with various disease parameters. Thirty SSc patients as well as 25 rheumatoid arthritis (RA) patients and 25 healthy volunteers were included in the present study. Organ system involvement in SSc patients was investigated. Pulmonary function tests as well as chest high-resolution computed tomography (HRCT) were done to detect pulmonary involvement in our patients. TRAIL concentrations were measured in the sera of SSc patients, RA patients and healthy controls by enzyme-linked immunosorbent assay. Mean serum TRAIL levels were significantly higher in SSc patients than in the control RA patients and in healthy controls (p < 0.001) while they were not significantly different between patients with diffuse cutaneous SSc and patients with limited cutaneous scleroderma. Serum TRAIL levels were significantly higher in SSc patients with pulmonary involvement and were significantly correlated with HRCT scores. Serum TRAIL levels are significantly elevated in SSc patients and are associated with SSc-associated pulmonary involvement denoting a possible role of TRAIL in the pathogenesis of SSc. Further studies may be needed to confirm these findings and the possible use of TRAIL in detection and possibly treatment of SSc-associated pulmonary disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.